JP2017506640A - 細胞外標的化薬物共役体 - Google Patents

細胞外標的化薬物共役体 Download PDF

Info

Publication number
JP2017506640A
JP2017506640A JP2016551824A JP2016551824A JP2017506640A JP 2017506640 A JP2017506640 A JP 2017506640A JP 2016551824 A JP2016551824 A JP 2016551824A JP 2016551824 A JP2016551824 A JP 2016551824A JP 2017506640 A JP2017506640 A JP 2017506640A
Authority
JP
Japan
Prior art keywords
antibody
edc
targeting moiety
drug
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016551824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506640A5 (enExample
Inventor
ジェイムズ アール． プルデント，
ジェイムズ アール． プルデント，
Original Assignee
セントローズ， エルエルシー
セントローズ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントローズ， エルエルシー, セントローズ， エルエルシー filed Critical セントローズ， エルエルシー
Publication of JP2017506640A publication Critical patent/JP2017506640A/ja
Publication of JP2017506640A5 publication Critical patent/JP2017506640A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016551824A 2014-02-14 2015-02-17 細胞外標的化薬物共役体 Pending JP2017506640A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461940219P 2014-02-14 2014-02-14
US61/940,219 2014-02-14
US201461946314P 2014-02-28 2014-02-28
US61/946,314 2014-02-28
PCT/US2015/016212 WO2015123687A1 (en) 2014-02-14 2015-02-17 Extracellular targeted drug conjugates

Publications (2)

Publication Number Publication Date
JP2017506640A true JP2017506640A (ja) 2017-03-09
JP2017506640A5 JP2017506640A5 (enExample) 2018-03-08

Family

ID=53800709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551824A Pending JP2017506640A (ja) 2014-02-14 2015-02-17 細胞外標的化薬物共役体

Country Status (4)

Country Link
US (2) US10675352B2 (enExample)
EP (1) EP3104882B1 (enExample)
JP (1) JP2017506640A (enExample)
WO (1) WO2015123687A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997009A (zh) * 2017-06-20 2020-04-10 索伦托治疗有限公司 Cd38抗体药物缀合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017023760A1 (en) 2015-07-31 2017-02-09 Prudent James R Extracellular drug conjugates targeting cd20
WO2017139698A1 (en) * 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
US12343394B2 (en) 2017-06-08 2025-07-01 Black Belt Therapeutics Limited CD38 modulating antibody agents
NZ759835A (en) 2017-06-08 2025-09-26 Black Belt Therapeutics Ltd Cd38 modulating antibody
EP3898701A4 (en) 2018-12-20 2022-10-26 Kleo Pharmaceuticals, Inc. COMBINATION THERAPY OF WEAPONS AND NATURAL KILLER CELLS
US20230028880A1 (en) * 2019-07-03 2023-01-26 Biohaven Therapeutics Ltd. Cd38-binding agents and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012178173A1 (en) * 2011-06-24 2012-12-27 Centrose, Llc Extracellular targeted drug conjugates
JP2013504585A (ja) * 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4364935A (en) 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
ES2338321T3 (es) 1992-08-21 2010-05-06 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
DK0616812T3 (da) 1993-03-24 2000-04-25 Berlex Biosciences Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2385743A1 (en) 1999-09-28 2001-04-05 Universitat Zurich Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
EP1174440A1 (en) * 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
CA2431600C (en) 2000-12-12 2012-04-17 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
CA2499300A1 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
IL316252A (en) * 2005-03-23 2024-12-01 Genmab As Antibodies against cd38 for treatment of multiple myeloma
JP2009507228A (ja) * 2005-08-31 2009-02-19 アフィーマックス・インコーポレイテッド プロキシマーカーを用いる生物学的流体およびその他の溶液マトリックス中の薬物の誘導体化および低レベル検出
WO2007140282A1 (en) * 2006-05-24 2007-12-06 Peg Biosciences Peg linker compounds and biologically active conjugates thereof
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN101520150A (zh) 2008-04-08 2009-09-02 王跃农 一种方便型节能吸顶灯
US20100017480A1 (en) 2008-07-17 2010-01-21 International Business Machines Corporation Recipient side grouping of addresses
US20120122514A1 (en) 2008-10-23 2012-05-17 Qualcomm Incorporated Selecting network service providers for multi-mode mobile devices
US8367419B2 (en) 2009-06-25 2013-02-05 Rutgers, The State University Of New Jersey Compositions and methods for detection of explosives
PT2580243T (pt) * 2010-06-09 2020-01-22 Genmab As Anticorpos contra cd38 humana
LT2621531T (lt) * 2010-09-27 2017-04-10 Morphosys Ag Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui
WO2012050884A2 (en) 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
EP2646107A2 (en) * 2010-12-01 2013-10-09 Spinal Modulation Inc. Agent delivery systems for selective neuromodulation
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US20130224228A1 (en) 2011-12-05 2013-08-29 Igenica, Inc. Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods
WO2017023760A1 (en) * 2015-07-31 2017-02-09 Prudent James R Extracellular drug conjugates targeting cd20
US20170049908A1 (en) * 2015-08-17 2017-02-23 Centrose, Llc Extracellular targeted drug conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504585A (ja) * 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
WO2012178173A1 (en) * 2011-06-24 2012-12-27 Centrose, Llc Extracellular targeted drug conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRONTIERS IN BIOSCIENCE, vol. 19, JPN6018042187, January 2014 (2014-01-01), pages 152 - 162, ISSN: 0003907240 *
PHYSIOLOGY, vol. 23, JPN7018003674, 2008, pages 205 - 211, ISSN: 0003907239 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997009A (zh) * 2017-06-20 2020-04-10 索伦托治疗有限公司 Cd38抗体药物缀合物

Also Published As

Publication number Publication date
EP3104882B1 (en) 2019-06-05
WO2015123687A1 (en) 2015-08-20
US20200384122A1 (en) 2020-12-10
EP3104882A1 (en) 2016-12-21
US10675352B2 (en) 2020-06-09
EP3104882A4 (en) 2017-11-22
US20160346403A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
KR102777693B1 (ko) Claudin18 항체 및 암 치료 방법
JP7682797B2 (ja) クローディン６二重特異性抗体
US20230072897A1 (en) Anti-b7-h4 antibody-drug conjugate and medicinal use thereof
US20200384122A1 (en) Extracellular targeted drug conjugates
KR102420934B1 (ko) 과글리코실화된 결합 폴리펩티드
AU2020294201A1 (en) Site-specific glycoengineering of targeting moieties
JP7682798B2 (ja) クローディン６抗体及び薬物複合体
JP7796230B2 (ja) Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体
CN107849132A (zh) 人源化的和亲和力成熟的针对FcRH5的抗体和使用方法
JP2014510080A (ja) 細胞外標的化薬物複合体
WO2021143741A1 (zh) 靶向多肽-药物缀合物及其用途
US20170049908A1 (en) Extracellular targeted drug conjugates
TW202432185A (zh) 配體－細胞毒性藥物綴合物及其藥物用途
JP2024542914A (ja) ヒトｃｘｃｌ１６抗体およびその使用
JP2023554215A (ja) 糖共役体
US20250074999A1 (en) Antibodies against lypd3
CN119074948A (zh) 靶向滋养层细胞表面糖蛋白抗原2的抗体药物偶联物
HK40125763A (en) Claudin-6 antibodies and drug conjugates
HK40108333A (zh) 双特异性抗体及使用方法
HK40067893A (en) Claudin-6 antibodies and drug conjugates
HK40067893B (en) Claudin-6 antibodies and drug conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190624